In a predefined subgroup analysis , leuprorelin treatment was associated with a greater reduction in barium residue after initial swallowing than was placebo in patients with a disease duration less than 10 years ( difference between groups -9.8 , -17.1 to -2.5 ; p = 0.009 ) .
